Feline Renal Amyloidosis

Feline renal amyloidosis is a progressive, potentially fatal protein misfolding disease in which insoluble amyloid fibrils—most commonly amyloid A (AA) type—deposit within renal tissues, impairing kidney architecture and function [1][2]. The condition can occur sporadically in mixed-breed cats, as a familial/hereditary disorder in certain breeds such as the Abyssinian, or as an outbreak-level phenomenon in overcrowded colony settings [2][3][6]. Amyloid deposits disrupt glomerular filtration and tubular integrity, ultimately leading to proteinuria, azotemia, and chronic or acute kidney failure [1][3]. Both a well-recognized hereditary form and an acquired, inflammation-driven form exist, making this disease clinically and pathologically heterogeneous.

AA Amyloidosis (Most Common Form)

The predominant form in cats is AA amyloidosis, in which serum amyloid A (SAA)—an acute-phase reactant protein produced by the liver in response to chronic inflammation or infection—is overproduced and undergoes misfolding into insoluble beta-pleated sheet fibrils [1][3]. These fibrils accumulate extracellularly within renal tissues, including glomeruli, cortical and medullary interstitium, and renal papillae [1][3][5]. Chronic or recurrent inflammatory stimuli (e.g., infectious diseases, overcrowding stress, chronic infections) are considered predisposing factors, particularly in shelter or colony cats [3].

SAA Polymorphisms and Intrarenal Distribution

Recent research has demonstrated that polymorphisms in the SAA protein itself influence the pattern of amyloid deposition within the kidney [5]. In mixed-breed cats, specific SAA isoforms were associated with differing distributions of glomerular versus papillary/medullary amyloid deposits, suggesting that genetic variation in SAA structure modifies where fibrils preferentially accumulate within the kidney [5]. This may partly explain the marked individual variation in clinical presentation and disease course.

Familial / Hereditary Form (Abyssinian Cats)

A well-characterized hereditary form exists in Abyssinian cats, in which medullary and glomerular amyloidosis occurs in related animals at significantly higher frequency than in the general population [2][6]. Potassium permanganate oxidation studies confirmed these deposits contain AA-type amyloid, implicating the same SAA precursor protein [2]. The inheritance pattern appears familial, and affected Abyssinian cats demonstrate medullary predominance of amyloid, often leading to papillary necrosis and secondary interstitial disease [2][6].

Colony/Overcrowding-Associated Form

In overcrowded multi-cat environments, high infectious burden and chronic physiological stress drive persistent elevation of SAA, predisposing entire colonies to AA amyloidosis [3]. Studies from Italy and Japan have documented high within-colony prevalence of renal amyloidosis, with Congo red-positive deposits identified prominently in glomeruli and cortical and medullary interstitium, confirming AA identity [1][3].

Concurrent Immune-Mediated Disease

There is evidence of concurrent immune-complex glomerulonephritis in some cats with renal amyloidosis, with immunofluorescence demonstrating granular deposits of feline IgG and C3 along glomerular capillary walls, suggesting complex interplay between amyloidosis and immune-mediated mechanisms [4].

Clinical Suspicion

Diagnosis should be suspected in any cat—particularly Abyssinian-breed cats, shelter cats, or colony cats—presenting with persistent proteinuria, azotemia, and signs of progressive kidney disease that are unexplained by more common causes such as pyelonephritis or polycystic kidney disease [1][2][6].

Laboratory Findings

Laboratory abnormalities commonly observed in affected cats include:

• ·Urine protein-to-creatinine ratio (UPC): Markedly elevated; persistent proteinuria is a hallmark and early indicator of renal AA amyloidosis [1]
• ·Serum creatinine (CREA) and BUN: Elevated, reflecting reduced glomerular filtration rate and azotemia; severity correlates with degree of amyloid deposition [1][3]
• ·Serum albumin (ALB): Low (hypoalbuminemia), due to heavy urinary protein loss [1][6]
• ·Serum globulins (GLOB): May be elevated, reflecting underlying chronic inflammation driving SAA production [1]
• ·Hematocrit (HCT): Reduced (normocytic, normochromic anemia) consistent with anemia of chronic kidney disease [6]
• ·Serum amyloid A (SAA): Elevated as an acute-phase protein in cats with concurrent inflammatory disease; can serve as a biomarker of risk [1]
• ·ALT: May be mildly elevated if hepatic amyloid deposition is concurrent, though hepatic involvement is less prominent than in some other species [1]
• ·Urine sediment: May be relatively inactive despite heavy proteinuria, which can be a distinguishing feature from immune-complex nephritis

Urine Protein Profiling and Biomarkers

Advanced urine protein electrophoresis and biomarker analysis have demonstrated specific urine protein profiles in cats with renal AA amyloidosis, potentially aiding noninvasive diagnosis and distinguishing amyloidosis from other causes of renal proteinuria [1].

Imaging

Renal ultrasound may reveal enlarged, hyperechoic kidneys in early stages, or shrunken, irregular kidneys in advanced disease; medullary or papillary calcification may be observed secondary to papillary necrosis in Abyssinian cats [2][6]. These findings are supportive but not diagnostic.

Definitive Diagnosis: Histopathology

Definitive diagnosis requires renal tissue examination via biopsy or necropsy [2][3]. Congo red staining of renal sections demonstrates characteristic apple-green birefringence under polarized light. AA typing is confirmed by potassium permanganate pre-treatment (which abolishes Congo red staining in AA but not AL amyloid) and/or immunohistochemistry using anti-SAA antibodies [2][3][5].

There is currently no treatment capable of reversing established amyloid deposits in feline renal amyloidosis. Management is centered on supportive care and addressing underlying inflammatory drivers.

Supportive Renal Management

• ·Intravenous or subcutaneous fluid therapy: To correct dehydration, support renal perfusion, and manage azotemia, particularly during acute exacerbations [3][6]
• ·Renal prescription diet: Low-phosphorus, moderate-protein diets are recommended to reduce uremic burden and slow progression of chronic kidney disease [6]
• ·Phosphate binders: Used when hyperphosphatemia is present to reduce renal secondary hyperparathyroidism
• ·Anti-emetics and appetite stimulants: Maropitant, mirtazapine, or other agents to manage uremic nausea and anorexia [6]

Antiproteinuric Therapy

• ·ACE inhibitors (e.g., benazepril) or angiotensin receptor blockers: May reduce intraglomerular pressure and proteinuria, though efficacy in amyloidosis is less well established than in immune-mediated nephropathies [6]
• ·Omega-3 fatty acids: Supplementation may have mild anti-inflammatory and renoprotective effects

Addressing Underlying Inflammation

• ·Identifying and treating chronic infectious or inflammatory conditions (e.g., dental disease, chronic respiratory infections, parasitism) is essential to reduce ongoing SAA production and slow amyloid accumulation [1][3]
• ·In colony settings, reduction of overcrowding and improvement of infectious disease management are critical interventions [3]

Colchicine

Colchicine has been used empirically in some cases of AA amyloidosis (primarily in humans and dogs) to reduce SAA production and potentially slow amyloid deposition; anecdotal veterinary use in cats has been described, but robust feline clinical trial evidence is lacking [6].

Dimethyl Sulfoxide (DMSO)

DMSO has been proposed as a possible amyloid-solubilizing agent in veterinary medicine, but clinical evidence in cats is insufficient to support routine use [6].

The prognosis for cats with renal amyloidosis is generally poor to grave, particularly once azotemia and significant proteinuria are established [1][2][3].

Mortality in Colony and Shelter Settings

A study of an overcrowded cat colony documented that multiple cats died of acute kidney injury attributable to renal amyloidosis, highlighting the potentially rapid and fatal nature of the disease in high-prevalence environments [3]. In an Italian shelter study, systemic AA amyloidosis was associated with azotemia and significant proteinuria, with affected cats having died or been euthanized due to disease severity [1]. The case-control design of that study—in which all subjects with renal amyloidosis had died or were euthanized—underscores the high case fatality [1].

Hereditary Form (Abyssinian Cats)

In the original description of familial renal amyloidosis in Abyssinian cats, all eight affected cats from two catteries were diagnosed at death or euthanasia, indicating that the condition was uniformly fatal once clinically apparent [2]. Survival time from clinical diagnosis is typically short in the absence of reversible causes.

Prognostic Indicators

• ·Degree of azotemia (CREA, BUN) and severity of proteinuria (UPC ratio) at diagnosis are key prognostic indicators [1]
• ·Cats with medullary predominance of amyloid (common in Abyssinian cats) and papillary necrosis have a particularly poor prognosis due to structural loss of renal architecture [2]
• ·Concurrent immune-complex nephritis may accelerate renal decline [4]

Note: Explicit published survival time statistics (e.g., median survival in days/months) are not provided in the currently cited literature. Given that virtually all described cases ended in death or euthanasia, the disease carries an extremely high case fatality rate once clinical signs are present [1][2][3].

Genetic Screening and Breeding Management

For hereditary forms in Abyssinian cats, avoidance of breeding from affected lineages is the most effective preventive measure [2][6]. Breeders should be advised that the condition appears to have a familial basis, and cats from affected catteries should not be used for reproduction [2][6].

Reduction of Chronic Inflammation

Since AA amyloidosis is driven by sustained elevation of SAA secondary to chronic inflammation or infection, minimizing infectious disease burden is the cornerstone of prevention in colony and shelter settings [1][3]:

• ·Control of infectious diseases: Vaccination against common feline infectious pathogens (FCV, FHV-1, FPV, FeLV) and regular screening for FIV and other chronic infections help reduce the inflammatory milieu [3]
• ·Dental care: Regular dental prophylaxis reduces a common source of chronic bacteremia and systemic inflammation
• ·Parasite control: Routine antiparasitic treatment minimizes chronic parasitic inflammatory stimulation

Environmental Management

• ·Reduction of overcrowding: High-density housing is a significant risk factor for colony-level outbreaks of renal amyloidosis; reducing cat density and improving sanitation in shelters and colonies are critical preventive measures [3]
• ·Stress reduction: Minimizing psychosocial stress in multi-cat environments may reduce chronic activation of the acute-phase response

Monitoring

Regular health monitoring of at-risk populations—particularly shelter cats and Abyssinian-breed cats—including periodic urinalysis (UPC ratio) and serum biochemistry, allows earlier detection of proteinuria and azotemia, enabling timely supportive intervention even if disease cannot be prevented [1][6].